Gundle Kenneth R, Punt Stephanie E, Conrad Iii Ernest U
Department of Orthopaedics & Sports Medicine, University of Washington Medical Center, 1959 Pacific Street NE, P. O. Box 356500, Seattle, WA 98195, USA.
Sarcoma. 2014;2014:947082. doi: 10.1155/2014/947082. Epub 2014 Dec 25.
In addition to patient reported outcome measures, accelerometers may provide useful information on the outcome of sarcoma patients treated with limb salvage. The StepWatch (SW) Activity Monitor (SAM) is a two-dimensional accelerometer worn on the ankle that records an objective measure of walking performance. The purpose of this study was to validate the SW in a cross-sectional population of adult patients with lower extremity sarcoma treated with limb salvage. The main outcome was correlation of total steps with the Toronto Extremity Salvage Score (TESS). In a sample of 29 patients, a mean of 12 days of SW data was collected per patient (range 6-16), with 2767 average total steps (S.D. 1867; range 406-7437). There was a moderate positive correlation between total steps and TESS (r = 0.56, P = 0.002). Patients with osseous tumors walked significantly less than those with soft tissue sarcoma (1882 versus 3715, P < 0.01). This study supports the validity of the SAM as an activity monitor for the objective assessment of real world physical function in sarcoma patients.
除了患者报告的结局指标外，加速度计可能会为接受保肢治疗的肉瘤患者的预后提供有用信息。StepWatch（SW）活动监测仪（SAM）是一种佩戴在脚踝上的二维加速度计，可记录步行表现的客观指标。本研究的目的是在接受保肢治疗的成年下肢肉瘤患者的横断面人群中验证SW。主要结局是总步数与多伦多肢体 salvage 评分（TESS）的相关性。在29例患者的样本中，每位患者平均收集了12天的SW数据（范围6 - 16天），平均总步数为2767步（标准差1867；范围406 - 7437步）。总步数与TESS之间存在中度正相关（r = 0.56，P = 0.002）。骨肿瘤患者的步行步数明显少于软组织肉瘤患者（1882步对3715步，P < 0.01）。本研究支持SAM作为活动监测仪在客观评估肉瘤患者实际身体功能方面的有效性。
